Aptahem confirms CMO Dr. Bylock’s responsibilities
Aptahem (publ) announced today that Dr. Anders Bylock, Chief Medical Officer (CMO), is taking on another part-time position effective immediately. Dr Bylock engagement with the company as CMO as well as chairman of the scientific advisory board is unchanged and he continues without diminished force.
Dr. Anders Bylock was appointed as the CMO of Aptahem in February 2018. In parallel, he is the chairman of the company’s scientific advisory board, which he first joined as a member in 2016. Dr Bylock adds a wealth of expertise following a long international career and experience in clinical development from renowned pharmaceutical companies such as Merck Sharpe & Dome (MSD) Sweden, AstraZeneca and Boehringer Ingelheim.
His responsibilities with Aptahem has not changed.
For further information:
Mikael Lindstam, CEO
Tel: 0766-33 36 99
Aptahem AB (APTA) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company’s primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in sepsis patients, among others. The company possesses patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.